Morgan Stanley’s Celgene Corporation Contingent Value Rights CELGZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-1,169
| Closed | -$1K | – | 6990 |
|
|
2019
Q3 | $1K | Buy |
1,169
+5
| +0.4% | +$3 | ﹤0.01% | 6611 |
|
|
2019
Q2 | $1K | Hold |
1,164
| – | – | ﹤0.01% | 6620 |
|
|
2019
Q1 | $1K | Hold |
1,164
| – | – | ﹤0.01% | 6569 |
|
|
2018
Q4 | $1K | Sell |
1,164
-300
| -20% | -$274 | ﹤0.01% | 6564 |
|
|
2018
Q3 | $2K | Sell |
1,464
-900
| -38% | -$1.2K | ﹤0.01% | 6603 |
|
|
2018
Q2 | $1K | Hold |
2,364
| – | – | ﹤0.01% | 6643 |
|
|
2018
Q1 | $1K | Hold |
2,364
| – | – | ﹤0.01% | 6585 |
|
|
2017
Q4 | $2K | Hold |
2,364
| – | – | ﹤0.01% | 6467 |
|
|
2017
Q3 | $4K | Hold |
2,364
| – | – | ﹤0.01% | 6344 |
|
|
2017
Q2 | $3K | Buy |
2,364
+1,125
| +91% | +$1.29K | ﹤0.01% | 6440 |
|
|
2017
Q1 | $1K | Hold |
1,239
| – | – | ﹤0.01% | 6544 |
|
|
2016
Q4 | $1K | Sell |
1,239
-5,450
| -81% | -$6.12K | ﹤0.01% | 6500 |
|
|
2016
Q3 | $7K | Hold |
6,689
| – | – | ﹤0.01% | 6192 |
|
|
2016
Q2 | $10K | Hold |
6,689
| – | – | ﹤0.01% | 6072 |
|
|
2016
Q1 | $8K | Sell |
6,689
-100
| -1% | -$134 | ﹤0.01% | 6198 |
|
|
2015
Q4 | $8K | Sell |
6,789
-1,100
| -14% | -$1.46K | ﹤0.01% | 6303 |
|
|
2015
Q3 | $12K | Sell |
7,889
-450
| -5% | -$868 | ﹤0.01% | 6205 |
|
|
2015
Q2 | $17K | Sell |
8,339
-9,050
| -52% | -$23.2K | ﹤0.01% | 6184 |
|
|
2015
Q1 | $51K | Sell |
17,389
-52
| -0.3% | -$165 | ﹤0.01% | 5790 |
|
|
2014
Q4 | $55K | Buy |
17,441
+8,875
| +104% | +$29.9K | ﹤0.01% | 5790 |
|
|
2014
Q3 | $29K | Buy |
8,566
+4,884
| +133% | +$14.2K | ﹤0.01% | 5900 |
|
|
2014
Q2 | $9K | Hold |
3,682
| – | – | ﹤0.01% | 6221 |
|
|
2014
Q1 | $11K | Sell |
3,682
-100
| -3% | -$302 | ﹤0.01% | 6120 |
|
|
2013
Q4 | $11K | Buy |
+3,782
| New | +$10.6K | ﹤0.01% | 6038 |
|
Morgan Stanley's CELGZ Position: Q4 2019 in Review
Morgan Stanley sold out of Celgene Corporation Contingent Value Rights (CELGZ) in Q4 2019, closing a stake of 1,169 shares — an estimated $1K sold.
Morgan Stanley first reported a position in CELGZ in Q4 2013 and held it in 24 quarters. The position peaked at $55K in Q4 2014. 0 funds tracked by Wall St. Rank hold CELGZ as of Q4 2019.
- Morgan Stanley reported no remaining Celgene Corporation Contingent Value Rights position as of Q4 2019 after selling out during the quarter.
- Morgan Stanley sold 1,169 Celgene Corporation Contingent Value Rights shares in Q4 2019, an estimated $1K.
- Morgan Stanley first reported a position in Celgene Corporation Contingent Value Rights in Q4 2013 and held it in 24 quarters.
- Morgan Stanley's Celgene Corporation Contingent Value Rights position peaked at $55K in Q4 2014.
- 0 funds tracked by Wall St. Rank held Celgene Corporation Contingent Value Rights as of Q4 2019.
Based on Morgan Stanley's 13F filing for Q4 2019, filed 14 Feb 2020.